These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 11239913

  • 1. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ, Brunk LK, Selley DE.
    Eur J Pharmacol; 2001 Mar 02; 414(2-3):135-43. PubMed ID: 11239913
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ, Martin BR.
    J Pharmacol Exp Ther; 2002 Oct 02; 303(1):36-44. PubMed ID: 12235230
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
    Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, Martin BR, Abood ME.
    Eur J Pharmacol; 1999 Jul 14; 377(1):117-25. PubMed ID: 10448934
    [Abstract] [Full Text] [Related]

  • 7. Regional differences in cannabinoid receptor/G-protein coupling in rat brain.
    Breivogel CS, Sim LJ, Childers SR.
    J Pharmacol Exp Ther; 1997 Sep 14; 282(3):1632-42. PubMed ID: 9316881
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.
    Mato S, Pazos A, Valdizán EM.
    Eur J Pharmacol; 2002 May 17; 443(1-3):43-6. PubMed ID: 12044790
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
    Ihenetu K, Molleman A, Parsons ME, Whelan CJ.
    Eur J Pharmacol; 2003 Jan 01; 458(1-2):207-15. PubMed ID: 12498928
    [Abstract] [Full Text] [Related]

  • 11. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.
    Mol Pharmacol; 2006 Jul 01; 70(1):41-50. PubMed ID: 16571654
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
    Ihenetu K, Molleman A, Parsons M, Whelan C.
    Eur J Pharmacol; 2003 Mar 19; 464(2-3):207-15. PubMed ID: 12620515
    [Abstract] [Full Text] [Related]

  • 13. Cannabinoid receptor stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding in rat brain membranes.
    Selley DE, Stark S, Sim LJ, Childers SR.
    Life Sci; 1996 Mar 19; 59(8):659-68. PubMed ID: 8761016
    [Abstract] [Full Text] [Related]

  • 14. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
    Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F.
    Eur J Pharmacol; 1999 Nov 12; 384(1):37-42. PubMed ID: 10611417
    [Abstract] [Full Text] [Related]

  • 15. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity.
    Breivogel CS, Selley DE, Childers SR.
    J Biol Chem; 1998 Jul 03; 273(27):16865-73. PubMed ID: 9642247
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB, Nalwalk JW, Stadel R, Timmerman H, Leurs R, Paria BC, Wang X, Dey SK.
    J Pharmacol Exp Ther; 2002 Oct 03; 303(1):314-22. PubMed ID: 12235266
    [Abstract] [Full Text] [Related]

  • 17. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.
    Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V.
    Eur J Neurosci; 2000 Jun 03; 12(6):2079-86. PubMed ID: 10886347
    [Abstract] [Full Text] [Related]

  • 18. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain.
    Sim LJ, Hampson RE, Deadwyler SA, Childers SR.
    J Neurosci; 1996 Dec 15; 16(24):8057-66. PubMed ID: 8987831
    [Abstract] [Full Text] [Related]

  • 19. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
    Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, Yamamura HI.
    Eur J Pharmacol; 1997 Feb 19; 321(1):R1-3. PubMed ID: 9083796
    [Abstract] [Full Text] [Related]

  • 20. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
    Liu Q, Bhat M, Bowen WD, Cheng J.
    J Pharmacol Exp Ther; 2009 Dec 19; 331(3):1062-70. PubMed ID: 19752241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.